Swiss drugmaker Basilea Pharmaceutica AG said Ronald Scott will retire as CEO.

David Veitch, Basilea's chief commercial officer, will replace Scott, effective April 19.

Veitch's previous roles include president of European operations at Savient Pharmaceuticals Inc. and senior vice president of Europe, the Middle East and Africa at Bristol-Myers Squibb Pharmaceuticals, a unit of Bristol-Myers Squibb Co.

Further, Daniel Lew and Thomas Rinderknecht will not stand for re-election at Basilea's annual general meeting April 18.